Day One Biopharmaceuticals (NASDAQ:DAWN) Issues Quarterly Earnings Results

Day One Biopharmaceuticals (NASDAQ:DAWN) released its quarterly earnings data on Tuesday. The company reported ($0.05) earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.75) by $0.70, Yahoo Finance reports. The company had revenue of $8.19 million during the quarter, compared to analysts’ expectations of $0.90 million.

Day One Biopharmaceuticals Price Performance

DAWN stock opened at $14.31 on Thursday. The firm’s fifty day simple moving average is $14.00 and its 200-day simple moving average is $14.84. Day One Biopharmaceuticals has a 12 month low of $9.67 and a 12 month high of $18.07. The company has a market capitalization of $1.25 billion, a P/E ratio of -5.70 and a beta of -1.51.

Insider Buying and Selling

In related news, General Counsel Adam Dubow sold 3,253 shares of the stock in a transaction on Thursday, May 16th. The shares were sold at an average price of $16.08, for a total transaction of $52,308.24. Following the sale, the general counsel now directly owns 21,731 shares of the company’s stock, valued at $349,434.48. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through this link. In other Day One Biopharmaceuticals news, General Counsel Adam Dubow sold 3,253 shares of the stock in a transaction on Thursday, May 16th. The shares were sold at an average price of $16.08, for a total transaction of $52,308.24. Following the transaction, the general counsel now directly owns 21,731 shares of the company’s stock, valued at $349,434.48. The transaction was disclosed in a legal filing with the SEC, which is accessible through the SEC website. Also, insider Samuel C. Blackman sold 20,000 shares of the stock in a transaction on Tuesday, July 16th. The shares were sold at an average price of $16.01, for a total transaction of $320,200.00. Following the transaction, the insider now directly owns 1,121,081 shares in the company, valued at $17,948,506.81. The disclosure for this sale can be found here. Over the last three months, insiders have sold 73,300 shares of company stock valued at $1,181,765. Corporate insiders own 8.40% of the company’s stock.

Analyst Upgrades and Downgrades

Several equities research analysts have recently commented on DAWN shares. JPMorgan Chase & Co. boosted their price target on shares of Day One Biopharmaceuticals from $32.00 to $36.00 and gave the company an “overweight” rating in a report on Monday, April 22nd. Wedbush reiterated an “outperform” rating and set a $33.00 price objective on shares of Day One Biopharmaceuticals in a research note on Thursday, July 25th. Piper Sandler reiterated an “overweight” rating and set a $40.00 price objective on shares of Day One Biopharmaceuticals in a research note on Monday, July 8th. Needham & Company LLC reiterated a “buy” rating and set a $33.00 price objective on shares of Day One Biopharmaceuticals in a research note on Tuesday. Finally, Bank of America upgraded shares of Day One Biopharmaceuticals from an “underperform” rating to a “buy” rating and boosted their price objective for the stock from $11.00 to $24.00 in a research note on Thursday. One equities research analyst has rated the stock with a hold rating and seven have assigned a buy rating to the company. Based on data from MarketBeat.com, the stock currently has an average rating of “Moderate Buy” and a consensus target price of $35.71.

About Day One Biopharmaceuticals

Day One Biopharmaceuticals, Inc, a clinical-stage biopharmaceutical company, develops and commercializes targeted therapies for patients with genomically defined cancers. Its lead product candidate is tovorafenib, an oral brain-penetrant type II pan-rapidly accelerated fibrosarcoma kinase inhibitor that is in Phase II clinical trial for pediatric patients with relapsed/ refractory low-grade glioma.